Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the ...

Johnson & Johnson ( JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to ...

The Wall Street Journal editorial board tore into President Donald Trump for pardoning the rioters who attacked the Capitol ...

The pharmaceutical company’s latest earnings exceeded Wall Street’s expectations as it braces for one of its top-selling ...

Project Stargate will see companies like Oracle, SoftBank, MGX, and OpenAI commit an initial $100 billion to build data ...

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...

Analysts on Wall Street project that Johnson & Johnson (JNJ) will announce quarterly earnings of $2 per share in its forthcoming report, representing a decline of 12.7% year over year. Revenues ...

Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in ...

NEW YORK — Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central nervous system disorders by purchasing Intra-Cellular Therapies. The health care giant said ...

Medical-technology and drug company's 2025 sales outlook is below consensus Johnson & Johnson's stock ... from Dow Jones Newswires and The Wall Street Journal. We sell different types of products ...